EDITOR'S CHOICE

SHORT REPORT

Mutations in *TMEM231* cause Joubert syndrome in French Canadians

Myriam Srour,[1] Fadi F Hamdan,[1] Jeremy A Schwartzentruber,[2] Lysanne Patry,[1] Luis H Ospina,[3] Michael I Shevell,[4] Valérie Désilets,[5] Sylvia Dobrzeniecka,[1] Géraldine Mathonnet,[5] Emmanuelle Lemyre,[5] Christine Massicotte,[1] Damian Labuda,[5] Dina Amrom,[1] Eva Andermann,[6] Guillaume Sébire,[7] Bruno Maranda,[8] FORGE Canada Consortium,[9] Guy A Rouleau,[10] Jacek Majewski,[2,6] Jacques L Michaud[1]

► Additional supplementary tables are published online only. To view these files please visit the journal online (http://dx.doi.org/10.1136/jmedgenet-2012-101132).

[1]Centre of Excellence in Neurosciences of Université de Montréal and Sainte-Justine Hospital Research Center, Montréal, Quebec, Canada
[2]McGill University and Genome Quebec Innovation Centre, Montréal, Quebec, Canada
[3]Department of Ophthalmology, Sainte-Justine Hospital Research Center, Montréal, Quebec, Canada
[4]Division of Pediatric Neurology, Montreal Children's Hospital-McGill University Health Center, Montreal, Quebec, Canada
[5]Division of Medical Genetics, Sainte Justine Hospital, Montréal, Quebec, Canada
[6]Department of Human Genetics, McGill University, Montréal, Quebec, Canada
[7]Division of Pediatric Neurology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada
[8]Division of Genetics, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada
[9]FORGE steering committee are listed in the acknowledgments
[10]Department of Medicine, Centre of Excellence in Neurosciences of Université de Montréal, Montréal, Quebec, Canada

Correspondence to
Dr Jacques L Michaud, Centre of Excellence in Neurosciences of Université de Montréal and Sainte-Justine Hospital Research Center, CHU Sainte-Justine, 3175 Côte Sainte-Catherine, Montreal, Quebec, Canada H3T 1C5; jacques.michaud@recherche-ste-justine.qc.ca

Received 22 June 2012
Revised 20 August 2012
Accepted 21 August 2012

ABSTRACT

Background Joubert syndrome (JBTS) is a predominantly autosomal recessive disorder characterised by a distinctive midhindbrain malformation, oculomotor apraxia, breathing abnormalities and developmental delay. JBTS is genetically heterogeneous, involving genes required for formation and function of non-motile cilia. Here we investigate the genetic basis of JBTS in 12 French–Canadian (FC) individuals.

Methods and results Exome sequencing in all subjects showed that six of them carried rare compound heterozygous mutations in *CC2D2A* or *C5ORF42*, known JBTS genes. In addition, three individuals (two families) were compound heterozygous for the same rare mutations in *TMEM231*(c.12T>A[p.Tyr4*]; c.625G>A[p.Asp209Asn]). All three subjects showed a severe neurological phenotype and variable presence of polydactyly, retinopathy and renal cysts. These mutations were not detected among 385 FC controls. TMEM231 has been previously shown to localise to the ciliary transition zone, and to interact with several JBTS gene products in a complex involved in the formation of the diffusion barrier between the cilia and plasma membrane. siRNA knockdown of TMEM231 was also shown to affect barrier integrity, resulting in a reduction of cilia formation and ciliary localisation of signalling receptors.

Conclusions Our data suggest that mutations in *TMEM231* cause JBTS, reinforcing the relationship between this condition and the disruption of the barrier at the ciliary transition zone.

Joubert syndrome (JBTS [MIM213300]) is a predominantly autosomal recessive disorder characterised by ocumolotor apraxia, abnormal breathing, ataxia and variable developmental delay or intellectual impairment (reviewed in Sattar *et al*).[1] A cardinal sign of JBTS is the presence of a complex midhindbrain malformation consisting of hypoplasia of the cerebellar vermis, abnormally deepened interpeduncular fossa at the level of the upper pons, and elongated and thickened superior cerebellar peduncles. This malformation takes the appearance of a molar tooth on MRI. Extraneurological manifestations, including retinopathy, renal cysts and polydactyly, are present in a subset of affected individuals. JBTS is genetically heterogeneous, with 17 genes described to date,[1–13] all of which appear to play a role in the development and/or function of non-motile cilia.

There is a high prevalence of JBTS in the French–Canadian (FC) population of the Lower Saint-Lawrence region of Quebec. We recently performed exome sequencing in 15 individuals (11 families) with JBTS from that region and found that mutations in *C5ORF42* explain JBTS in nine individuals (seven families).[12] In addition, we identified pathogenic compound heterozygous mutations in *CC2D2A*, a previously known JBTS gene, in two affected individuals from two different families. The genetic basis of JBTS remained unexplained in four individuals (two families) from this initial study. Here, we follow-up on our previous investigation by performing exome sequencing in eight additional individuals with JBTS (six unrelated families) originating from other regions of Quebec.

The six probands had a molar tooth sign on imaging, and variable expression of the classical JBTS features. The two additional individuals are the uncle (II-4) and aunt (II-6) of subject IV-1 in family 385/447. These individuals were considered to have a variable expression of JBTS as they both had oculomotor apraxia and, additionally, II-4 had gait ataxia and a history of developmental delay. Brain MRI was normal in II-6 (see online supplementary figure S1, A-B) but was not done in II-4. Informed consent was obtained from each individual or legal guardian. This study was approved by our institutional ethics committee. Genomic DNA from each sample was captured with the Agilent SureSelect 50 Mb exome capture oligonucleotide library, and the captured DNA was sequenced with paired-end 100 bp reads on Illumina HiSeq 2000 resulting in an average of 12.7 gigabases (Gb) of raw sequence for each sample. Data were analysed as previously described.[14] After removing putative PCR-generated duplicate reads using Picard (V.1.48), we aligned reads to human genome assembly hg19 using a Burroughs–Wheeler algorithm (BWA V.0.5.9). Median read depth of bases in consensus coding sequence (CCDS) exons was 99 (determined with Broad Institute Genome Analysis Toolkit V.1.0.4418).[15] On average, 87% (±2.0%) of bases in CCDS exons were covered by at least 20 reads. We called sequence variants using Samtools (V.0.1.17) mpileup and varFilter, and required at least three variant reads as well as

≥20% variant reads for each called position, with Phred-like quality scores of at least 20 for single nucleotide variants (SNVs) and at least 50 for small insertions or deletions (indels). We used Annovar and custom scripts to annotate variants according to the type of mutation, occurrence in the Single Nucleotide Polymorphism database (dbSNP), Sorting Intolerant from Tolerant (SIFT) score, 1000 Genomes allele frequency, and National Heart, Lung and Blood Institute (NHLBI) exomes allele frequency.[16] To identify potentially pathogenic variants we filtered out (1) synonymous variants or intronic variants other than those affecting the consensus splice sites; (2) variants seen in more than two of 416 exomes from patients with rare, monogenic diseases unrelated to JBTS that were sequenced at the McGill University and Genome Quebec Innovation Centre and (3) variants with a frequency greater than 0.5% in either the 1000 genomes or NHLBI exome datasets.

We first examined the eight exome datasets to look for rare variants in the 17 known JBTS genes (*INPP5E*[MIM613037], *TMEM216*[MIM613277], *AHI1*[MIM608894], *NPHP1* [MIM607100], *CEP290*[MIM610142], *TMEM67*[MIM609884], *RPGRIP1L*[MIM610937], *ARL13B*[MIM608922], *CC2D2A* [MIM612013], *CXORF5*[MIM300170], *KIF7*[MIM611254], *TCTN1* [MIM609863], *TCTN2*[MIM613885], *TMEM237* [MIM614424], *CEP41*[MIM610523], *TMEM138*[MIM614459], *C5ORF42*[MIM614571],[1–13] as well as in the JBTS candidate gene *TTC21B*(MIM612014).[17] Five individuals from three families (II-1 from family 379, II-4, II-6 and IV-1 from family 385/447, and II-1 from family 492 online supplementary figure S2) were each found to carry two rare heterozygous variants in *CC2D2A*(NM_001080522.2). One in-frame amino acid deletion (c.3450_3452del[p.Val1151del]) and four different missense variants (c.3376G>A[p.Glu1126Lys], c.4559A>G[p.Asn1520Ser], c.4667A>T[p.Asp1556Val], c.4702T>C[p.Tyr1568His]) were identified, two of which, c.3376G>A(p.Glu1126Lys) and c.4667A>T(p.Asp1556Val), were identified previously in FC individuals with JBTS.[12] The novel mutations c.4559A>G(p.Asn1520Ser) and c.4702T>C(p.Tyr1568His) are predicted to be damaging (by SIFT, Polyphen-2 and Mutation Taster) and neither variant has been reported in the Exome Variant Server (EVS; NHLBI GO Exome Sequencing Project), dbSNP135 or 1000 Genome datasets. These five *CC2D2A* mutations cluster in either the C2 domain (amino acids 1062–1174) or the C-terminal part of the protein, as do most missenses that cause JBTS.[18] Segregation analysis revealed that all the affected individuals, but none of their unaffected relatives, were compound heterozygous for the mutations (see online supplementary figure S1). We conclude that these mutations are pathogenic and responsible for JBTS in these five individuals.

We also identified a frameshift mutation (c.8257_8258insA [p.Lys2753fs]) and a splice-site mutation (c.7400+1G>A) in *C5ORF42*(NM_023073.3) in individual II-2 from family 551. Sanger sequencing showed that the proband is compound heterozygous for these mutations. The splice site (c.7400+1G>A) mutation has been previously identified in patients with JBTS and shown to result in skipping of exon 35 and the creation of a premature stop codon while c.8257_8258insA(p.Lys2753fs), which is novel, is predicted to truncate *C5ORF42* in the middle of its sequence, close to where other truncating mutations have been previously identified in JBTS patients.[12] Both *C5ORF42* mutations are thus considered pathogenic in this individual. Table 1 summarises the genotypes and phenotypes of these patients with mutations in *CC2D2A* and *C5ORF42*, as well as those of FC patients previously described with mutations in these genes. Individuals in our cohort with mutations in *CC2D2A* do not have any extraneural manifestations, and appear to have a milder phenotype, with all affected individuals walking independently before the age of 4 years, and intelligence ranging from normal to mild intellectual impairment. Individuals with mutations in *C5ORF42* have a more variable phenotype. They have borderline to moderate cognitive impairment and variable age at walking, ranging between 30 months and 8 years. Some patients also showed limb abnormalities, including one individual with combined pre- and postaxial polydactyly, an unusual finding in JBTS, which is typically associated with postaxial polydactyly.

We then combined the exome data of the two remaining individuals with unexplained JBTS and the exome data of four individuals with unexplained JBTS from our previous study,[12] making a total of six individuals from four different families. We analysed the data by looking for protein-coding genes that contained homozygous or multiple heterozygous variants in each affected individual. For multiplex families, we only considered genes with the same variants in the affected siblings (see online supplementary tables S1 and S2). Only one gene, *TMEM231*, harboured multiple rare mutations in more than one family. Three JBTS individuals from 2 families (II-1 and II-2 from family 387, and II-1 from family 483) harboured the same two variants in *TMEM231*(NM_001077418.1): c.12T>A (p.Tyr4*) and c.625G>A(p.Asp209Asn). Sanger sequencing showed that all affected individuals were compound heterozygous for these variants (figure 1A). The c.12T>A(p.Tyr4*) mutation targets exon 1 of the canonical isoform of *TMEM231* (NM_001077418.1; ENST00000258173), as well as the two other predicted protein-coding isoforms reported in the Ensemble Genome Browser. In ENST00000565067, it leads to the same nonsense change (p.Tyr4*), while in the longer isoform ENST00000398114, it abolishes the translation initiation methionine (c.2T>A[p.Met1?]), which would likely prevent translation of this isoform due to the absence of any other in-frame methionine in exons 1 and 2. The c.625G>A(p.Asp209Asn) causes the same amino acid change in the different *TMEM231* predicted isoforms (figure 1C). It affects a highly conserved amino acid (figure 1D), and is predicted to be damaging by Polyphen-2 and Mutation Taster but not by SIFT. Both p.Tyr4* and p.Asp209N are extremely rare. Among the 416 in-house exomes, the c.12T>A(p.Tyr4*) was not found, and the c.625G>A(p.Asp209Asn) variant was seen in the heterozygous state in one FC individual. No additional *TMEM231* coding/splicing variants were present in this individual's exome. To determine the carrier rate of c.625G>A and c.12T>A, we genotyped 385 healthy FC controls by Sanger sequencing, but did not find any carriers of either of these mutations, indicating that they are very rare. Only p.Asp209Asn is reported in the heterozygous state in the 1000 genomes and EVS, but at a very low frequency (0.01%), while p.Tyr4* is not reported in any of these public single nucleotide polymorphism (SNP) databases. Furthermore, no truncating mutations in *TMEM231* were seen in 416 control exomes of patients with other rare diseases, and only one other truncating variant (stopgain SNV) is reported in EVS, at a frequency of 0.04%. For the three individuals with compound heterozygous *TMEM231* mutations, we examined all SNV genotypes in regions surrounding the two mutations. This revealed a region of shared genotypes (two shared haplotypes) extending over at least 1.7 Mb, suggesting the existence of founder effects (see online supplementary table S3).

The three individuals with mutations in *TMEM231* are among the most severely affected in our French–Canadian JBTS

Table 1 Genotypes and phenotypes of French Canadian individuals with JBTS

	Srour *et al*[12]												This study								
	406/301			394		474	480	489	479	468	473	484	385/447			379	492	551	387		483
Genotypes	IV-1	IV-2	IV-3	II-1	II-2	II-1	II-1	II-1	II-1	II-1	II-2	II-1	II-4	II-6	IV-1	II-1	II-1	II-2	II-1	II-2	II-1
C5ORF42																					
c.4006C>T(p.Arg1336Trp)	+	–	–	+	+	+	+	–	+	+	–	–	–	–	–	–	–	–	–	–	–
c.7400+1G>A	+	+	+	+	+		+	–	–	–	–	–	–	–	–	–	–	+	–	–	–
c.6407del(p.Pro2136Hisfs*31)	–	–	–	–	–	+	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
c.7477C>T(p.Arg2493*)	–	–	–	–	–	–	–	+	–	–	–	–	–	–	–	–	–	–	–	–	–
c.4804C>T(p.Arg1602*)	–	–	–	–	–	–	–	–	+	–	–	–	–	–	–	–	–	–	–	–	–
c.7957+288G>A; c.4690G>A(p.Ala1564Thr)	–	+	+	–	–	–	–	+	–	+	–	–	–	–	–	–	–	–	–	–	–
c.8257_8258insA(p.K2753fs)	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	+	–	–	–
CC2D2A																					
c.4667A>T(p.Asp1556Val)	–	–	–	–	–	–	–	–	–	–	+	+	–	–	+	–	+	–	–	–	–
c.3376G>A(p.Glu1126Lys)	–	–	–	–	–	–	–	–	–	–	+	+	+	+	+	+	–	–	–	–	––
c.4559A>G(p.Asn1520Ser)	–	–	–	–	–	–	–	–	–	–	–	–	+	+	–	–	–	–	–	–	–
c.4702T>C(p.Tyr1568His)	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	+	–	–	–	–	–
c.3450_3452del(p.Val1151del)	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-	-	+	-	-	-	-
TMEM231																					
c.12T>A(p.Tyr4*)	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	+	+	+
c.625G>A(p.Asp209Asn)	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	+	+	+
Age (years)	8	1.5	3	52	45	4	10	7	13	31	3	12	62	53	5	10	5	16	14	9	4
Developmental delay	+	+	+	+	+	+	+	+	+	+	Mild	Mild	+	–	+	+	+	+	+	+	+
Age at walking	Walks with aid	Not amb	NA	NA walks	3	Not amb	8	3.5	7	2.5	1.5	1.5	4	1	2	4	2.5	7	Not amb	Not amb	Not amb
Oculomotor apraxia	–	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	–	+	+	+
Breathing abnormality	+	+	+	+	+	+	+	+	–	–	–	–	–	–	–	+	–	+	+	+	+
Limb abnormality†	–	+	–	–	–	+	–	–	–	–	–	–	–	–	–	–	–	–	–	+	+
Brain MRI	MTS	MTS	MTS	ND	MTS	MTS	MTS	MTS	MTS	MTS	MTS	MTS	NA	N	MTS	MTS	MTS	MTS	MTS	MTS	MTS
Retinal involvement‡	–(f)	–(e)	–(e)	–(h)	–(h)	–(f)	–(e)	–(e)	–(f)	–(h)	–(e)	–(e)	–(f)	–(e)	–(e)	–(e)	–(e)	–(f)	–(f)	+(f)	+(e)
Renal involvement§	–(us)	–(us)	–(us)	–(h)	–(h)	–(us)	– (us)	–(us)	–(us)	–(h)	–(us)	–(h)	–(h)	–(h)	–(us)	–(us)	–(h)	–(us)	–(us)	+(us)	+(us)

The nucleotide and amino acid positions for *CC2D2A* are based on reference sequence #NM_001080522.2, for *TMEM231*on reference sequence #NM_001077418.1, and for *C5ORF42* on reference sequence #NM_023073.3 except for c.G4690A/p.A1564T that is based on ENSEMBLE transcript ID #ENST00000509849.
†IV-2 from family 406/301 has a 3–4 syndactyly in the left hand, II-1 from family 474 has pre- and postaxial polydactyly of the four limbs, and II-2 from family 387 and II-1 from family 483 have postaxial polydactyly and 4-5-6 syndactyly of the right foot.
‡Retinal involvement was determined by electroretinogram (erg), fundoscopy (f) or history (h).
§Renal involvement was determined by renal ultrasound (us) or history (h). Individuals II-2 from family 387 and II-1 from family 483 have renal cysts with normal renal function.
MTS, Molar tooth sign; N, normal; NA, not available; Not amb, Not ambulatory.



Figure 1 (A) Segregation of mutations in *TMEM231* in JBTS families. (B) Brain MRI from individual II-1 from family 387 showing the 'molar tooth sign'. (C) Left panel, scheme showing the presence of the mutations with respect to the different *TMEM231* Ensemble-annotated transcripts predicted to produce proteins; right panel, the corresponding TMEM231 proteins are depicted in the right panel. TM, denotes the presence of a transmembrane domain, as predicted by *SMART* algorithm. (D) Amino acid conservation of the residues affected by the p.Tyr4* and p.Asp209Asn mutations in TMEM231. Amino acid alignments were generated using homologene (NCBI).

cohort. They are dependent in all activities of daily living, are non-verbal, and can take steps only if assisted with a walker. Both siblings from family 387 had significant aggressive and self-mutilating behaviour consisting of head banging and biting, requiring treatment with antipsychotic agents, mouth guard and protective helmet. Individuals II-2 from family 387 and II-1 from family 483 show extraneural manifestations consisting of retinopathy, bilateral macroscopic renal cysts (but normal renal function), and postaxial polysyndactyly of one foot (table 1 and see online supplementary figure S1, D-F).

The presence of rare and potentially deleterious mutations in *TMEM231*, which segregate with the disease in two unrelated FC families, strongly suggests that disruption of this gene causes JBTS in our subjects. The fact that the three individuals with the mutations in *TMEM231* show a similar form of JBTS also supports the involvement of this gene. Furthermore, several observations indicate that *TMEM231* plays a key role in the cilia, and physically interacts with known JBTS genes. *TMEM231* encodes a transmembrane protein that localises at the base of the ciliary axoneme at the transition zone.[19] Recently, TMEM231 was shown to be part of the B9 complex, which is required for a diffusion barrier between the cilia and plasma membranes that maintains the integrity of the cilia as a privileged membrane domain.[19] The B9 complex includes at least 13 proteins (BD91, BD92, TCTN1, TCTN2, TCTN3, CC2D2A, TMEM216, TMEM67, TMEM237, TMEM231, MKS1, AHI1, TMEM17), all of which, with two exceptions (TCTN3, TMEM17), are involved in JBTS and/or Meckel–Gruber syndrome (MKS), a related ciliopathy.[19 20] Proteomic studies using the MKS proteins BD91 or BD92 as baits have shown that TMEM231 is in a complex with TCTN1, TCTN2, MKS1, AHI1 and CC2D2A.[19] siRNA knockdown of TMEM231 disrupts the integrity of the ciliary barrier and the localisation of components of the B9 complex at the transition zone, resulting in a reduction of cilia formation and ciliary localisation of signalling receptors.[19] TMEM231 knockout mice die at E15.5 with severe vascular defects, and display typical features of ciliopathy, namely microphthalmia, polydactyly and

abnormalities in patterning of ventral spinal cord.[19] Altogether, these observations indicate that autosomal-recessive mutations in *TMEM231* are a cause of JBTS.

JBTS in FCs show both locus and allelic heterogeneity. We identified three JBTS genes in this population with a total of 14 different alleles. Three mutations in *C5ORF42*, two mutations in *CC2D2A* and two mutations in *TMEM231* were found in at least two unrelated affected individuals (table 1). Our analysis indicates that each of these mutations is located within a distinct haplotype in these individuals, suggesting the existence of multiple founder effects.[12] Founder effects are typically associated with an increase in the frequency of a specific autosomal recessive allele, which is often accompanied by other alleles that remain at their usual background frequency. Interestingly, for each of these three JBTS genes, we found at least two founding mutations. It is likely that more of these complex founder effects will be unravelled with the use of genomic sequencing.

In summary, combining this study and our previous one, we were able to explain the underlying genetic cause of JBTS in 21/24 FC individuals using exome sequencing. In the course of this work, we identified *TMEM231* as a novel JBTS gene. This discovery gives further support to the concept that JBTS results from disruption of the barrier at the ciliary transition zone.

Acknowledgements Foremost, we thank the families who generously contributed their time and materials to this research study. This work was selected for study by the FORGE Canada Steering Committee, consisting of K Boycott (University Ottawa), J Friedman (University of British Columbia), J Michaud (Université de Montréal), F Bernier (University Calgary), M Brudno (University Toronto), B Fernandez (Memorial University), B Knoppers (McGill University), M Samuels (Université de Montréal), and S. Scherer (University of Toronto). We would like to thank Janet Marcadier (Clinical Coordinator) and Chandree Beaulieu (Project Manager) for their contribution to the infrastructure of the FORGE Canada Consortium. The authors wish to acknowledge the contribution of the high-throughput sequencing platform of the McGill University and Génome Québec Innovation Centre, Montréal, Canada. JL Michaud is a National Scholar from the Fonds de la Recherche en Santé du Québec (FRSQ). M Srour holds a CIHR clinician-scientist training award.

Contributors MS, FFH, JM, JLM: study design, data analysis and interpretation and manuscript writing and revision. JS: data analysis and manuscript writing and revision. GM, EL, LP, SD: laboratory follow-up of candidate variants and segregation studies. MS, JLM, LHO, MIS, VD, DA, EA, GS, BM: patient recruitment, examination and counselling. DL, GAR: contribution of control samples. CM: coordination of samples and patient consents.

Funding This work was funded by the Government of Canada through Genome Canada, the Canadian Institutes of Health Research (CIHR) and the Ontario Genomics Institute (OGI-049).

Competing interests None.

Ethics approval Ethics Committee of Sainte Justine Research Center.

Provenance and peer review Not commissioned; externally peer reviewed.

WEB RESOURCES 1000 Genomes Project, http://browser.1000genomes.org/index.html
dbSNP, http://www.ncbi.nlm.nih.gov/projects/SNP/
Ensemble Genome Browser: http://www.ensembl.org
ESP Exome Variant Serve (EVS)r: http://evs.gs.washington.edu/EVS/
Gene Ontology, http://www.geneontology.org/
Mutation Taster: http://www.mutationtaster.org/
NCBI homologene, http://www.ncbi.nlm.nih.gov/homologene
NCBI Nucleotide database, http://www.ncbi.nlm.nih.gov/nuccore
Online Mendelian Inheritance in Man (OMIM), http://www.omim.org
Polyphen-2: http://genetics.bwh.harvard.edu/pph2/
SIFT: http://sift.jcvi.org/
SMART sequence analysis: http://smart.embl-heidelberg.de/

REFERENCES

1. **Sattar S,** Gleeson JG. The ciliopathies in neuronal development: a clinical approach to investigation of Joubert syndrome and Joubert syndrome-related disorders. *Dev Med Child Neurol* 2011;**53**:793–8.
2. **Bielas SL,** Silhavy JL, Brancati F, Kisseleva MV, Al-Gazali L, Sztriha L, Bayoumi RA, Zaki MS, Abdel-Aleem A, Rosti RO, Kayserili H, Swistun D, Scott LC, Bertini E, Boltshauser E, Fazzi E, Travaglini L, Field SJ, Gayral S, Jacoby M, Schurmans S, Dallapiccola B, Majerus PW, Valente EM, Gleeson JG. Mutations in INPP5E, encoding inositol polyphosphate-5-phosphatase E, link phosphatidyl inositol signaling to the ciliopathies. *Nat Genet* 2009;**41**:1032–6.
3. **Edvardson S,** Shaag A, Zenvirt S, Erlich Y, Hannon GJ, Shanske AL, Gomori JM, Ekstein J, Elpeleg O. Joubert syndrome 2 (JBTS2) in Ashkenazi Jews is associated with a TMEM216 mutation. *Am J Hum Genet* 2010;**86**:93–7.
4. **Baala L,** Romano S, Khaddour R, Saunier S, Smith UM, Audollent S, Ozilou C, Faivre L, Laurent N, Foliguet B, Munnich A, Lyonnet S, Salomon R, Encha-Razavi F, Gubler MC, Boddaert N, de Lonlay P, Johnson CA, Vekemans M, Antignac C, Attie-Bitach T. The Meckel-Gruber syndrome gene, MKS3, is mutated in Joubert syndrome. *Am J Hum Genet* 2007;**80**:186–94.
5. **Cantagrel V,** Silhavy JL, Bielas SL, Swistun D, Marsh SE, Bertrand JY, Audollent S, Attié-Bitach T, Holden KR, Dobyns WB, Traver D, Al-Gazali L, Ali BR, Lindner TH, Caspary T, Otto EA, Hildebrandt F, Glass IA, Logan CV, Johnson CA, Bennett C, Brancati FA, International Joubert Syndrome Related Disorders Study Group, Valente EM, Woods CG, Gleeson JG. Mutations in the cilia gene ARL13B lead to the classical form of Joubert syndrome. Am J Hum Genet 2008;83:170–9.
6. **Dafinger C,** Liebau MC, Elsayed SM, Hellenbroich Y, Boltshauser E, Korenke GC, Fabretti F, Janecke AR, Ebermann I, Nürnberg G, Nürnberg P, Zentgraf H, Koerber F, Addicks K, Elsobky E, Benzing T, Schermer B, Bolz HJ. Mutations in KIF7 link Joubert syndrome with Sonic Hedgehog signaling and microtubule dynamics. *J Clin Invest* 2011;**121**:2662–7.
7. **Garcia-Gonzalo FR,** Corbit KC, Sirerol-Piquer MS, Ramaswami G, Otto EA, Noriega TR, Seol AD, Robinson JF, Bennett CL, Josifova DJ, García-Verdugo JM, Katsanis N, Hildebrandt F, Reiter JF. A transition zone complex regulates mammalian ciliogenesis and ciliary membrane composition. *Nat Genet* 2011;**43**:776–84.
8. **Sang L,** Miller JJ, Corbit KC, Giles RH, Brauer MJ, Otto EA, Baye LM, Wen X, Scales SJ, Kwong M, Huntzicker EG, Sfakianos MK, Sandoval W, Bazan JF, Kulkarni P, Garcia-Gonzalo FR, Seol AD, O'Toole JF, Held S, Reutter HM, Lane WS, Rafiq MA, Noor A, Ansar M, Devi AR, Sheffield VC, Slusarski DC, Vincent JB, Doherty DA, Hildebrandt F, Reiter JF, Jackson PK. Mapping the NPHP-JBTS-MKS protein network reveals ciliopathy disease genes and pathways. *Cell* 2011;**145**:513–28.
9. **Huang L,** Szymanska K, Jensen VL, Janecke AR, Innes AM, Davis EE, Frosk P, Li C, Willer JR, Chodirker BN, Greenberg CR, McLeod DR, Bernier FP, Chudley AE, Müller T, Shboul M, Logan CV, Loucks CM, Beaulieu CL, Bowie RV, Bell SM, Adkins J, Zuniga FI, Ross KD, Wang J, Ban MR, Becker C, Nürnberg P, Douglas S, Craft CM, Akimenko MA, Hegele RA, Ober C, Utermann G, Bolz HJ, Bulman DE, Katsanis N, Blacque OE, Doherty D, Parboosingh JS, Leroux MR, Johnson CA, Boycott KM. TMEM237 is mutated in individuals with a Joubert syndrome related disorder and expands the role of the TMEM family at the ciliary transition zone. *Am J Hum Genet* 2011;**89**:713–30.
10. **Lee JE,** Silhavy JL, Zaki MS, Schroth J, Bielas SL, Marsh SE, Olvera J, Brancati F, Iannicelli M, Ikegami K, Schlossman AM, Merriman B, Attié-Bitach T, Logan CV, Glass IA, Cluckey A, Louie CM, Lee JH, Raynes HR, Rapin I, Castroviejo IP, Setou M, Barbot C, Boltshauser E, Nelson SF, Hildebrandt F, Johnson CA, Doherty DA, Valente EM, Gleeson JG. CEP41 is mutated in Joubert syndrome and is required for tubulin glutamylation at the cilium. *Nat Genet* 2012;**44**:193–9.
11. **Lee JH,** Silhavy JL, Lee JE, Al-Gazali L, Thomas S, Davis EE, Bielas SL, Hill KJ, Iannicelli M, Brancati F, Gabriel SB, Russ C, Logan CV, Sharif SM, Bennett CP, Abe M, Hildebrandt F, Diplas BH, Attié-Bitach T, Katsanis N, Rajab A, Koul R, Sztriha L, Waters ER, Ferro-Novick S, Woods CG, Johnson CA, Valente EM, Zaki MS, Gleeson JG. Evolutionarily assembled cis-regulatory module at a human ciliopathy locus. *Science* 2012;**335**:966–9.
12. **Srour M,** Schwartzentruber J, Hamdan FF, Ospina LH, Patry L, Labuda D, Massicotte C, Dobrzeniecka S, Capo-Chichi JM, Papillon-Cavanagh S, Samuels ME, Boycott KM, Shevell MI, Laframboise R, Désilets V, FORGE Canada Consortium, Maranda B, Rouleau GA, Majewski J, Michaud JL. Mutations in C5ORF42 cause Joubert syndrome in the French Canadian population. *Am J Hum Genet* 2012;**90**:693–700.
13. **Valente EM,** Logan CV, Mougou-Zerelli S, Lee JH, Silhavy JL, Brancati F, Iannicelli M, Travaglini L, Romani S, Illi B, Adams M, Szymanska K, Mazzotta A, Lee JE, Tolentino JC, Swistun D, Salpietro CD, Fede C, Gabriel S, Russ C, Cibulskis K, Sougnez C, Hildebrandt F, Otto EA, Held S, Diplas BH, Davis EE, Mikula M Strom CM, Ben-Zeev B, Lev D, Sagie TL, Michelson M, Yaron Y, Krause A, Boltshauser E, Elkhartoufi N, Roume J, Shalev S, Munnich A, Saunier S, Inglehearn C, Saad A, Alkindy A, Thomas S, Vekemans M, Dallapiccola B, Katsanis N, Johnson CA, Attié-Bitach T, Gleeson JG. Mutations in TMEM216 perturb ciliogenesis and cause Joubert, Meckel and related syndromes. *Nat Genet* 2010;**42**:619–25.
14. **McKenna A,** Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* 2010;**20**:1297–303.
15. **Wang K,** Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res* 2010;**38**:e164.

16. **Kumar P,** Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc* 2009;**4**:1073–81.
17. **Davis EE,** Zhang Q, Liu Q, Diplas BH, Davey LM, Hartley J, Stoetzel C, Szymanska K, Ramaswami G, Logan CV, Muzny DM, Young AC, Wheeler DA, Cruz P, Morgan M, Lewis LR, Cherukuri P, Maskeri B, Hansen NF, Mullikin JC, Blakesley RW, Bouffard GG; NISC Comparative Sequencing Program, Gyapay G, Rieger S, Tönshoff B, Kern I, Soliman NA, Neuhaus TJ, Swoboda KJ, Kayserili H, Gallagher TE, Lewis RA, Bergmann C, Otto EA, Saunier S, Scambler PJ, Beales PL, Gleeson JG, Maher ER, Attié-Bitach T, Dollfus H, Johnson CA, Green ED, Gibbs RA, Hildebrandt F, Pierce EA, Katsanis N. TTC21B contributes both causal and modifying alleles across the ciliopathy spectrum. Nat Genet 2011;43:189–96.
18. **Bachmann-Gagescu R,** Ishak GE, Dempsey JC, Adkins J, O'Day D, Phelps IG, Gunay-Aygun M, Kline AD, Szczaluba K, Martorell L, Alswaid A, Alrasheed S Pai S, Izatt L, Ronan A, Parisi MA, Mefford H, Glass I, Doherty D. Genotype-phenotype correlation in CC2D2A-related Joubert syndrome reveals an association with ventriculomegaly and seizures. *J Med Genet* 2012;**49**:126–37.
19. **Chih B,** Liu P, Chinn Y, Chalouni C, Komuves LG, Hass PE, Sandoval W, Peterson AS. A ciliopathy complex at the transition zone protects the cilia as a privileged membrane domain. *Nat Cell Biol* 2012;**14**:61–72.
20. **Czarnecki PG,** Shah JV. The ciliary transition zone: from morphology and molecules to medicine. *Trends Cell Biol* 2012;**22**:201–10.

Supplemental Figure 1: Segregation studies of mutations in *CC2D2A* (NM_001080522.2) in families 385/447, 379 and 492, and of mutations in *C5ORF42* (NM_023073.3) in family 551.



Supplemental Figure 2: Sagittal T1(A) and axial T2 (B) brain MRI of individual II:6 from family 385/447 who has compound heterozygous mutations in *CC2D2A*, and ocumolotor apraxia as the sole manifestation. Right (C) and left (D) renal ultrasounds from individual II:2 from family 387 with compound heterozygous mutations in *TMEM231* showing macroscopic cysts (arrows). Post-axial polysyndactyly in individual II:1 from family 483 (Ei and ii) and II:2 from family 387 (F i and ii).



Supplemental Table 1. Analysis of combined exome sequences from the 6 individuals (from 4 families) with unexplained JBTS

Variant prioritization steps in the combined exomes dataset	
Filters applied (sequentially)	***Number of variants retained***
Non-synonymous/splicing/coding indel variants	19884
After excluding variants present in > 2 in-house exomes	1035
After excluding variants reported in 1000 genomes and EVS datasets (frequency > 0.5%)	987

*Total number of variants identified in the combined 6 exomes; redundant variants were counted only once.

Supplemental Table 2. Genes with rare homozygous or multiple heterozygous variants in the 6 individuals (from 4 families) with unexplained JBTS

Number of families with mutations in the same gene	Number of genes	Genes
1 family	19	*C14orf135,C9orf174,CLCN1, ENTPD3,FBXL22,FCGR3B,FLG,LRRK2,MUC12,PDE8A,PPL,PUS10, RASIP1,RCC2,SHROOM4,TACC3,* ***TMEM231****, TRAF5,TTN*
2 families	1	***TMEM231***
> 2 families	0	-

Supplemental Table 3: This table shows the called genotypes for SNVs upstream and downstream of the two TMEM231 mutations reported. SNVs are included until 4 discordant SNVs are seen.Only positions where all three of the samples had at least 10 reads of coverage are included. Regions with lower than average mapping quality (below 50) have genotypes shown as "?", since the lower quality of mapping in these regions indicates that genotype calls may not be accurate.Positions with discordant genotypes are shown in red text. The two TMEM231 mutations are highlighted in yellow.

Position	rsID	Ref	MAF from 1000genom	EVS MAF	Sample 1329-483	Sample 998_387	Sample 997_387
chr16:72993708	rs62640010	C	0.0298	0.032309	C/T	C/C	C/C
chr16:72993831	rs7193297	A	0.4322	0.471418	A/C	A/A	A/A
chr16:72993860	rs62639999	G	0.0238	0.03756	G/G	G/A	G/A
chr16:73126750	rs72795164	G	0.022		G/G	G/A	G/A
chr16:73126858	rs7189194	T	0.9945	0.011149	G/G	G/G	G/G
chr16:74255440	.	G			G/C	G/C	G/C
chr16:74425548	rs2868591	A		0.362811	G/G	G/G	G/G
chr16:74443433	rs62055232	C		0.138795	?	?	?
chr16:74444361	rs3931746	C			?	?	?
chr16:74444384	rs60469648	C		0.180212	?	?	?
chr16:74444538	.	G		0.149081	?	?	?
chr16:74444838	rs62054261	A	0.4954	0.272234	?	?	?
chr16:74444976	.	C		0.003845	?	?	?
chr16:74445003	.	C			?	?	?
chr16:74445142	rs55906605	C			?	?	?
chr16:74445689	rs62054260	C	0.1145	0.091932	?	?	?
chr16:74445817	rs2650552	C			?	?	?
chr16:74447514	rs2650549	T		0.036624	?	?	?
chr16:74451884	rs78597831	C			?	?	?
chr16:74499668	.	C		9.30E-05	C/T	C/T	C/T
chr16:74501856	rs6564117	C	0.7051		G/G	G/G	G/G
chr16:74503078	rs79193356	T	0.0508		T/C	T/C	T/C
chr16:74504005	rs2303279	T	0.7253	0.215932	T/C	T/C	T/C
chr16:74504097	rs12716764	G	0.9881		C/C	C/C	C/C
chr16:74513985	rs918781	C	0.951		T/T	T/T	T/T
chr16:74517155	rs2303281	A	0.7248		G/G	G/G	G/G
chr16:74519533	rs968649	C	0.9675		A/A	A/A	A/A
chr16:74526752	rs2010910	G	0.9895		A/A	A/A	A/A
chr16:74537591	rs4887772	C	0.7038	0.33984	T/T	T/T	T/T
chr16:74660174	rs12933037	G	0.4103		G/A	G/A	G/A
chr16:74662597	rs11149759	C	0.3214	0.249117	C/T	C/T	C/T
chr16:74664743	rs7193541	T	0.418	0.454545	T/C	T/C	T/C
chr16:74664810	rs7188880	A	0.6305	0.398587	T/T	T/T	T/T
chr16:74664969	rs7193959	T	0.745		A/A	A/A	A/A
chr16:74666634	rs4072450	G	0.7431		C/C	C/C	C/C
chr16:74670458	rs4888262	C	0.6305	0.399052	T/T	T/T	T/T
chr16:74694692	rs56143602	T	0.4066		T/C	T/C	T/C
chr16:74695079	rs8058922	G	0.7605	0.272448	T/T	T/T	T/T
chr16:74706298	rs4888274	A	0.6255		T/T	T/T	T/T
chr16:74709737	rs7184423	C	0.3947		C/A	C/A	C/A
chr16:74712905	rs6564158	A	0.6474	0.387897	A/T	A/T	A/T
chr16:74750396	rs11554621	T	0.1305	0.170385	T/C	T/C	T/C
chr16:74750405	rs2301865	G	0.7546	0.218628	A/A	A/A	A/A
chr16:74752841	rs6564161	C	0.1287	0.169057	C/G	C/G	C/G

Pseudogenes make the read mappings here ambiguous and many of the genotypes may be wrong

chr16:74753079	rs2074629	C	0.2784	0.299684	C/T	C/T	C/T	
chr16:74876541	rs4550476	T	0.9835		C/C	C/C	C/C	
chr16:74876612	rs4328467	G	0.6232		G/A	G/A	G/A	
chr16:74876991	rs7187659	T	0.9382		C/C	C/C	C/C	
chr16:74877062	rs12444292	T	0.1827		T/C	T/C	T/C	
chr16:74877063	rs12446306	G	0.185		G/A	G/A	G/A	
chr16:74877125	rs9930887	G	0.3347		G/A	G/A	G/A	
chr16:74877693	rs79940172	A			A/G	A/G	A/G	
chr16:74877694	rs7187950	C	0.6886		C/T	C/T	C/T	
chr16:74877733	rs12923470	A	0.3063		A/G	A/G	A/G	
chr16:74877754	rs12922918	C	0.3049		C/T	C/T	C/T	
chr16:74877844	rs7186814	G	0.6694		G/A	G/A	G/A	
chr16:74920090	rs9936830	T	0.1799		T/C	T/C	T/C	
chr16:74920191	rs14308	G	0.1113	0.160625	G/A	G/A	G/A	
chr16:74920374	rs4888305	C	0.9487		T/T	T/T	T/T	
chr16:74921661	rs9940014	A	0.168	0.233408	A/T	A/T	A/T	
chr16:74926520	rs11149776	C	0.2601	0.292517	C/T	C/T	C/T	
chr16:74943260	rs2303254	A	0.6662		G/G	G/G	G/G	
chr16:75019070	rs3814875	C	0.331		A/A	A/A	A/A	
chr16:75148647	.	G	0.0023		G/A	G/A	G/A	
chr16:75186727	rs11859007	G	0.7766		A/A	A/A	A/A	
chr16:75200378	rs9929570	T	0.9153		C/C	C/C	C/C	
chr16:75200407	rs11865310	G	0.7761		C/C	C/C	C/C	
chr16:75200416	rs7200789	T	0.9139		C/C	C/C	C/C	
chr16:75201060	rs6564215	T	0.7321		C/C	C/C	C/C	
chr16:75202998	rs12716783	A	0.7798		C/C	C/C	C/C	
chr16:75226297	rs118133067	T	0.0545		T/C	T/C	T/C	
chr16:75238103	rs4737	C	0.8246	0.248094	T/T	T/T	T/T	
chr16:75258617	rs2287990	C	0.1461	0.109221	C/T	C/T	C/T	
chr16:75263974	rs6564241	T	0.9226		C/C	C/C	C/C	
chr16:75269267	rs3169330	A	0.9144	0.154365	G/G	G/G	G/G	
chr16:75269534	rs3743613	C	0.4625	0.305581	C/T	C/T	C/T	
chr16:75270721	rs2278020	C	0.5169	0.359617	C/A	C/A	C/A	
chr16:75276295	rs7195938	A	0.9148		G/G	G/G	G/G	
chr16:75276775	rs1035539	G	0.6016	0.42466	G/A	G/A	G/A	
chr16:75277344	rs4888363	A	0.8471	0.233012	T/T	T/T	T/T	
chr16:75277480	rs4887810	C	0.4922		C/A	C/A	C/A	
chr16:75281964	rs1862737	A	0.5266	0.476976	A/C	A/C	A/C	
chr16:75327916	rs2073619	A	0.7624	0.166853	A/G	A/G	A/G	
chr16:75338855	rs3743607	C	0.3558		C/T	C/T	C/T	
chr16:75339131	rs7192981	T	0.9844	0.025126	G/G	G/G	G/G	
chr16:75445605	rs1109341	G	0.5238		G/A	G/A	G/A	
chr16:75445675	rs1109342	G	0.5234	0.498605	G/A	G/A	G/A	
chr16:75445906	rs247435	C	0.9895		T/T	T/T	T/T	
chr16:75445971	rs247436	T	0.2207		T/G	T/G	T/G	
chr16:75448273	rs8056236	C	0.5252		C/T	C/T	C/T	
chr16:75448659	rs8051407	A	0.5238		A/G	A/G	A/G	
chr16:75563330	rs3826107	G	0.163	0.170106	G/A	G/A	G/A	
chr16:75563746	rs8048818	T	0.2147	0.237821	T/G	T/G	T/G	
chr16:75573884	rs2242407	T	0.2386	0.242384	T/C	T/C	T/C	
chr16:75575410	rs7202717	G	0.1593		G/A	G/A	G/A	
chr16:75576539	.	C		9.90E-05	C/T	C/T	C/T	
chr16:75579111	rs4149500	G	0.1589		?	?	?	

V1231

chr16:75579233	rs2738801	A	0.2505	0.254407	?	?	?	TMEM
chr16:75579470	rs2550894	T			?	?	?	
chr16:75579924	rs8055668	A	0.2491		?	?	?	
chr16:75590096	.	A			A/T	A/T	A/T	
chr16:75634014	rs7206481	A	0.2038		A/G	A/G	A/G	
chr16:75646685	rs3743598	G	0.5261	0.368284	G/T	G/T	G/T	
chr16:75654031	rs11648478	A	0.0911		A/T	A/T	A/T	
chr16:75667954	rs6564270	C	0.2088		C/T	C/T	C/T	
chr16:75670128	rs2289064	C	0.0668		C/A	C/A	C/A	
chr16:76268960	rs11861749	T	0.4913		T/C	T/C	T/C	
chr16:76269501	.	G	0.0082		G/A	G/A	G/A	
chr16:76461273	rs7192076	A	0.7042		A/C	C/C	A/C	
chr16:76461519	rs9927638	C	0.4217	0.39961	C/C	C/A	C/C	
chr16:76461588	rs9938200	A	0.7047		A/G	G/G	A/G	
chr16:76481824	rs35839511	C	0.3292		C/C	C/A	C/C	